BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.

View in: PubMed

subject areas

Adult
Aged
Antimetabolites, Antineoplastic
Biomarkers, Tumor
Capecitabine
Circulating Tumor DNA
Clinical Decision-Making
Disease-Free Survival
Female
High-Throughput Nucleotide Sequencing
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasm, Residual
Patient Selection
Precision Medicine
Predictive Value of Tests
Time Factors
Triple Negative Breast Neoplasms

authors with profiles

Rita Nanda